CD274 and neoplasm: There are disparities among the IHC assays for PD-L1 expression in terms of the cell populations assayed (tumor cells [TCs] or tumor-infiltrating immune cells [ICs]), the type of detection antibodies used, and the cutoff values for scoring, making it difficult to generalize their results (24–27).